TY  - JOUR
AU  - Mai, Elias K
AU  - Huhn, Stefanie
AU  - Miah, Kaya
AU  - Poos, Alexandra M
AU  - Scheid, Christof
AU  - Weisel, Katja C
AU  - Bertsch, Uta
AU  - Munder, Markus
AU  - Berlanga, Oscar
AU  - Hose, Dirk
AU  - Seckinger, Anja
AU  - Jauch, Anna
AU  - Blau, Igor W
AU  - Hänel, Mathias
AU  - Salwender, Hans J
AU  - Benner, Axel
AU  - Raab, Marc S
AU  - Goldschmidt, Hartmut
AU  - Weinhold, Niels
TI  - Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma.
JO  - Blood cancer journal
VL  - 13
IS  - 1
SN  - 2044-5385
CY  - London [u.a.]
PB  - Nature Publishing Group
M1  - DKFZ-2023-00048
SP  - 1
PY  - 2023
AB  - Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. We included 480 transplant-eligible newly-diagnosed multiple myeloma (MM) patients from the GMMG-MM5 trial (EudraCT No. 2010-019173-16) and performed a retrospective MS analysis at baseline (480 patients) and at the pre-defined, consecutive time points after induction (444 patients), prior to maintenance (305 patients) and after one year of maintenance (227 patients). We found that MS negativity was significantly associated with improved progression-free survival (PFS) even in patients with complete response (CR) at all investigated follow-up time points. The prognostic impact was independent of established risk factors, such as the revised International Staging System. Combining MS and baseline cytogenetics improved the prediction of outcome: MS-positive patients with high-risk cytogenetics had a dismal PFS of 1.9 years (95
KW  - Humans
KW  - Multiple Myeloma: therapy
KW  - Multiple Myeloma: drug therapy
KW  - Prognosis
KW  - Treatment Outcome
KW  - Retrospective Studies
KW  - Bone Marrow
KW  - Neoplasm, Residual: diagnosis
LB  - PUB:(DE-HGF)16
C6  - pmid:36599831
C2  - pmc:PMC9812999
DO  - DOI:10.1038/s41408-022-00772-9
UR  - https://inrepo02.dkfz.de/record/186679
ER  -